Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Forest Laboratories
Age
18–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
male and female outpatients 18 to 64 years of age
Females must be post-menopausal, or not pregnant and using an approved contraceptive regimen
stage 2 diastolic hypertension (DBP \>= 100 mmHg)
You may not be if
secondary hypertension
evidence of other concurrent disease or conditions that might interfere with the conduct of the study
participation in an investigational drug study within 30 days or 5 half-lives, whichever is longer, of Screening (Visit 1).
have a history of hypersensitivity to nebivolol or other β-blockers, or any contraindication to β-blocker use
Clareo Health | Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension
